Injeção intravítrea de triancinolona no tratamento da telangiectasia retiniana justafoveolar idiopática

Júnior, Otacílio Oliveira Maia; Takahashi, Walter Yukihiko; Bonanomi, Maria Teresa Bc; Nascimento, Vinícius Paganini; Melo, Carlos Sérgio Nascimento de

doi:10.1590/s0004-27492006000600028

Cited by 4 publications

(2 citation statements)

References 19 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This outcome was not as good as those reported in eyes with retinitis pigmentosa (3,5) and other exudative diseases (2,6) , in which total resorption of edema, with recovery of foveal depression is usually achieved, at least for some time. In fact, most of these exudative diseases show incompetence of inner hematoretinal barrier, that can be stabilized with IVTA (2,6) . It is possible that the outer hematoretinal barrier affected in GA and retinitis pigmentosa, for instance, may be less susceptible to IVTAmediated stabilization.…”

Section: Discussioncontrasting

confidence: 78%

Macular edema associated with gyrate atrophy managed with intravitreal triamcinolone: a case report

Vasconcelos-Santos¹,

Magalhães²,

Nehemy³

2007

Arq. Bras. Oftalmol.

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 78%

Macular edema associated with gyrate atrophy managed with intravitreal triamcinolone: a case report

Vasconcelos-Santos¹,

Magalhães²,

Nehemy³

2007

Arq. Bras. Oftalmol.

View full text Add to dashboard Cite

show abstract

“…An improvement of visual acuity could be observed in 1 of these 2 subjects [23]. Case reports and a few small series have not shown convincing efficacy of intravitreal triamcinolone or grid laser in improving vision [24,25,26]. …”

Section: Introductionmentioning

confidence: 99%

Reduced-Fluence Photodynamic Therapy Combined with Ranibizumab for Nonproliferative Macular Telangiectasia Type 2

Zehetner¹,

Haas²,

B³

et al. 2013

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To report the efficacy of reduced-fluence photodynamic therapy (PDT) combined with intravitreal ranibizumab for the treatment of nonproliferative macular telangiectasia (MacTel) type 2. Methods: Noncomparative, interventional, retrospective case series; 5 eyes of 4 patients were studied. Patients were treated with reduced-fluence PDT and intravitreal ranibizumab within 24 h. After initial treatment, follow-up was at least 12 months in all patients. Results: At baseline median logMAR (logarithm of the minimal angle of resolution) best-corrected visual acuity (BCVA) was 1.0 (range, 1.0-0.3). At 3 months of follow-up vision increased in 3 out of 5 eyes and median BCVA was 0.4 (range, 1.0-0.2). The gain of BCVA ranged from 6 lines to 1 line. Visual acuity remained stable in the other 2 study eyes. No eyes lost vision at 3 months of follow-up. At 12 months of follow-up median logMAR BCVA was 0.7 (range, 1.3-0.3). Two eyes had maintained their gain in BCVA compared to baseline. Two eyes lost vision compared to baseline and 1 eye showed unchanged visual acuity at 12 months of follow-up. Conclusion: A combination therapy with reduced-fluence PDT and intravitreal ranibizumab might be a valuable treatment option for eyes with progressive vision loss due to nonproliferative MacTel type 2.

show abstract

Macular telangiectasia type 2

Issa

Gillies

Chew

et al. 2013

Progress in Retinal and Eye Research

303

230

View full text Add to dashboard Cite

Macular telangiectasia type 2 is a bilateral disease of unknown cause with characteristic alterations of the macular capillary network and neurosensory atrophy. Its prevalence may be underestimated and has recently been shown to be as high as 0.1% in persons 40 years and older. Biomicroscopy may show reduced retinal transparency, crystalline deposits, mildly ectatic capillaries, blunted venules, retinal pigment plaques, foveal atrophy, and neovascular complexes. Fluorescein angiography shows telangiectatic capillaries predominantly temporal to the foveola in the early phase and a diffuse hyperfluorescence in the late phase. High-resolution optical coherence tomography (OCT) may reveal disruption of the photoreceptor inner segment–outer segment border, hyporeflective cavities at the level of the inner or outer retina, and atrophy of the retina in later stages. Macular telangiectasia type 2 shows a unique depletion of the macular pigment in the central retina and recent therapeutic trials showed that such depleted areas cannot re-accumulate lutein and zeaxanthin after oral supplementation. There have been various therapeutic approaches with limited or no efficacy. Recent clinical trials with compounds that block vascular endothelial growth factor (VEGF) have established the role of VEGF in the pathophysiology of the disease, but have not shown significant efficacy, at least for the nonneovascular disease stages. Recent progress in structure–function correlation may help to develop surrogate outcome measures for future clinical trials. In this review article, we summarize the current knowledge on macular telangiectasia type 2, including the epidemiology, the genetics, the clinical findings, the staging and the differential diagnosis of the disease. Findings using retinal imaging are discussed, including fluorescein angiography, OCT, adaptive optics imaging, confocal scanning laser ophthalmoscopy, and fundus autofluorescence, as are the findings using visual function testing including visual acuity and fundus-controlled microperimetry. We provide an overview of the therapeutic approaches for both non-neovascular and neovascular disease stages and provide a perspective of future directions including animal models and potential therapeutic approaches.

show abstract

Injeção intravítrea de triancinolona no tratamento da telangiectasia retiniana justafoveolar idiopática

Abstract: Intravitreal triamcinolone injection in the treatment of idiopathic juxtafoveal telangiectasis Trabalho desenvolvido no Setor de Retina e Vítreo do

Cited by 4 publications

References 19 publications

Macular edema associated with gyrate atrophy managed with intravitreal triamcinolone: a case report

Macular edema associated with gyrate atrophy managed with intravitreal triamcinolone: a case report

Reduced-Fluence Photodynamic Therapy Combined with Ranibizumab for Nonproliferative Macular Telangiectasia Type 2

Macular telangiectasia type 2

Contact Info

Product

Resources

About